Curt LaBelle
Managing Partner & President @ Global Health Investment Fund (GHIF)
New York, United States
Curt LaBelle is a Series A investor at Global Health Investment Fund (GHIF) in New York focused on Biotechnology and Medical. Curt LaBelle has been investing in and working with healthcare companies for two decades. As the Founding Partner and Chair of Global Health Funds, Curt oversees the private investments portfolio, actively investing the AXA Prime Fund and serving as Managing Partner of the pioneering Global Health Investment Fund, where he continues to generateattractive financial returns while delivering life-changing therapeutics and diagnostics worldwide for conditions such as cholera, cataract-induced blindness, snakebites, tuberculosis, HIV, and postpartum hemorrhage. Curt holds a dual MD/MBA degree from Columbia University.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Curt LaBelle invests in
Stages Curt LaBelle invests in
Countries Curt LaBelle invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Medical 3 (43%)
- Health Care 3 (43%)
- Medical Device 3 (43%)
- Manufacturing 1 (14%)
Stage
- Series A 2 (29%)
- Series B 2 (29%)
- Series C 2 (29%)
- Series E 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening. | $26M / Series A / Jul 17, 2024 | ||
| Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | ||
| Ophirex, is developing a first in class drug that will help the 500,000 people who die or suffer amputations each year from venomous snakebite. 70% of those who die never even make it to the hospital for treatment. Because Ophirex's drug will be available in an oral formulation, all that will change. Our drug is a small molecule inhibitor thattargets the most lethal component of venom, so it will be effective against the most dangerous snakes. | $37M / Series B / Jan 05, 2023 | ||
| CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally. | $32M / Series A / Sep 30, 2022 | ||
| Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Their single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. They are devoted to improving the lives of womenaround the world. | $13.9M / Series C / Jul 30, 2020 | ||
| Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Their single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. They are devoted to improving the lives of womenaround the world. | $10.3M / Series B / Aug 28, 2018 | ||
| Iantech has developed advanced micro-interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-interventional technique designed to deliver energy-free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgicaltechnique.At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world | $4.5M / Series C / Jul 13, 2017 |
Co-Investors
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Global Health Investment Fund (GHIF) Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Curt LaBelle
Managing Partner & President
|
|||
Kabeer Aziz
Associate
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Curt LaBelle invest in?
Curt LaBelle invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Curt LaBelle?
Public channels for Curt LaBelle include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Curt LaBelle last invest?
The most recent investment recorded for Curt LaBelle closed in Jul 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
